ACE Inhibitors and ARBs

Blocking the renin-angiotensin system (RAS) is a cornerstone strategy for managing hypertension, heart failure, and chronic kidney disease. ACE inhibitors and ARBs represent two pivotal drug classes that interrupt this pathway at different points, offering powerful cardiovascular and renal protection. Understanding their distinct mechanisms, clinical applications, and adverse effect profiles is essential for safe and effective prescribing, particularly given their widespread use in chronic conditions.

The Renin-Angiotensin System: The Therapeutic Target

To understand how ACE inhibitors and ARBs work, you must first grasp the system they inhibit. The renin-angiotensin system is a hormonal cascade that regulates blood pressure, fluid volume, and electrolyte balance. When renal perfusion drops or sodium levels are low, the kidneys release renin. Renin converts angiotensinogen (from the liver) into angiotensin I, a mostly inactive peptide. Angiotensin-converting enzyme (ACE), predominantly found in the lungs and endothelium, then converts angiotensin I into the potent angiotensin II.

Angiotensin II exerts its effects primarily by binding to the AT1 receptor, leading to:

• Vasoconstriction of arteries, increasing systemic vascular resistance and blood pressure.
• Stimulation of aldosterone secretion from the adrenal glands, causing sodium and water retention (and potassium excretion).
• Promotion of cardiac and vascular remodeling (hypertrophy and fibrosis).
• Direct stimulation of thirst in the brain.

Pharmacologic blockade of this cascade at either the ACE level or the AT1 receptor level mitigates these harmful effects, making these drugs foundational in cardiology and nephrology.

ACE Inhibitors: Blocking the Conversion Enzyme

Angiotensin-converting enzyme (ACE) inhibitors prevent the formation of angiotensin II by competitively inhibiting the ACE enzyme. Their names typically end in "-pril."

Mechanism of Action: By blocking ACE, these drugs directly reduce levels of angiotensin II. This leads to vasodilation, reduced aldosterone secretion (decreasing sodium/water retention and increasing serum potassium), and diminished harmful tissue remodeling. However, ACE is also responsible for breaking down other substances, most notably bradykinin. With ACE inhibited, bradykinin accumulation occurs in the lungs and other tissues, which mediates both a beneficial vasodilatory effect and the class's most characteristic adverse effects.

Key Examples and Notes:

• Captopril: The first orally active ACE inhibitor. It has a shorter duration of action and a sulfhydryl group in its structure, which is rarely associated with rash or taste disturbance.
• Enalapril: A prodrug that is metabolized in the liver to its active form, enalaprilat. This allows for better oral bioavailability.
• Lisinopril: A long-acting ACE inhibitor that is not a prodrug; it is active as administered. It is one of the most commonly prescribed drugs in its class.

The primary therapeutic outcomes are a reduction in blood pressure, a decrease in afterload in heart failure, and renal protective effects, especially in patients with diabetic nephropathy, where they reduce proteinuria and slow disease progression.

Angiotensin II Receptor Blockers (ARBs): Selective Receptor Antagonism

Angiotensin II receptor blockers (ARBs) take a different, more selective approach. Instead of preventing angiotensin II formation, they competitively block the AT1 receptor, through which angiotensin II exerts almost all of its known detrimental cardiovascular effects. Their names end in "-sartan."

Mechanism of Action: By selectively antagonizing the AT1 receptor, ARBs prevent angiotensin II from binding, effectively shutting down the downstream cascade of vasoconstriction, aldosterone release, and remodeling. Importantly, because they do not inhibit ACE, they do not cause bradykinin accumulation. This key pharmacological difference explains their distinct adverse effect profile. Angiotensin II levels may actually increase with ARB use, but it cannot signal through the blocked AT1 receptor.

Key Examples and Notes:

• Losartan: The first ARB. It is a prodrug with an active metabolite and has a shorter half-life than many later agents.
• Valsartan: A potent, non-prodrug ARB commonly used for hypertension, heart failure, and post-myocardial infarction.

ARBs produce hemodynamic and protective benefits very similar to ACE inhibitors—reducing blood pressure, improving heart failure outcomes, and providing renal protective effects in diabetic nephropathy. They are often used when ACE inhibitors are not tolerated.

Clinical Comparison: Efficacy, Side Effects, and Monitoring

While both classes are first-line for hypertension and are crucial in heart failure management, their differences lie in side effect profiles and specific clinical considerations.

Adverse Effects of ACE Inhibitors:

• Dry Cough: This is the most common reason for discontinuation, occurring in up to 20% of patients. It is a persistent, tickling, non-productive cough caused by bradykinin accumulation in the lungs. Switching to an ARB typically resolves it.
• Angioedema: A rare but potentially life-threatening adverse effect, also linked to bradykinin. It involves swelling of the face, lips, tongue, and larynx, which can obstruct the airway. It is a medical emergency. The risk is higher in Black patients.
• Hyperkalemia: Reduced aldosterone decreases potassium excretion. Risk is heightened in patients with renal impairment, diabetes, or those on potassium-sparing diuretics or supplements. Regular monitoring of serum potassium and renal function is mandatory.
• Contraindication in Pregnancy: Both ACE inhibitors and ARBs are contraindicated as they can cause fetal injury, including renal dysplasia, oligohydramnios, and skull hypoplasia.

Adverse Effects of ARBs: ARBs are generally better tolerated because they avoid bradykinin-mediated effects. They do not cause the characteristic dry cough or angioedema (risk is far lower). However, they share the risks of hyperkalemia, acute kidney injury (especially in volume-depleted states), and are equally contraindicated in pregnancy.

Renal Protection: Both classes are pivotal in slowing the progression of diabetic nephropathy. They reduce intraglomerular pressure and proteinuria by dilating the efferent arteriole of the glomerulus more than the afferent arteriole. This unique hemodynamic effect decreases the filtration force and glomerular damage.

Common Pitfalls

1. Initiating Therapy without Assessing Volume Status: Starting an ACE inhibitor or ARB in a patient who is volume-depleted (e.g., on high-dose diuretics) can cause a precipitous drop in glomerular filtration rate (GFR), leading to acute kidney injury. Always evaluate volume status and consider holding diuretics for a day or two when initiating therapy.

1. Neglecting Baseline and Routine Monitoring: Failure to check baseline serum creatinine, estimated GFR, and potassium before starting therapy, and not scheduling follow-up labs within 1-2 weeks (and periodically thereafter), is a major error. This monitoring is critical for detecting hyperkalemia or a significant decline in renal function.

1. Misattributing a Dry Cough: Dismissing a new, persistent dry cough in a patient on an ACE inhibitor as "just a cold" can delay switching to an ARB and unnecessarily impact the patient's quality of life and adherence. Always consider the drug as the primary etiology.

1. Combining with NSAIDs: Concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) with an ACE inhibitor or ARB dramatically increases the risk of acute kidney injury and can blunt the antihypertensive effect. This common drug interaction must be actively avoided or managed with extreme caution.

Summary

• ACE inhibitors (e.g., lisinopril, enalapril) block the conversion of angiotensin I to angiotensin II, leading to bradykinin accumulation, which causes their signature dry cough and angioedema risk.
• ARBs (e.g., losartan, valsartan) selectively block the AT1 receptor, preventing angiotensin II action without affecting bradykinin, thus avoiding cough and having a lower angioedema risk.
• Both classes are essential for treating hypertension, heart failure, and providing renal protective effects in diabetic nephropathy by reducing proteinuria and intraglomerular pressure.
• Hyperkalemia is a shared, serious adverse effect requiring consistent laboratory monitoring of potassium and renal function, especially at therapy initiation.
• Both drug classes are absolutely contraindicated in pregnancy due to risks of fetal malformation and injury.